38 results about "NASAL PREPARATIONS" patented technology

A nasal spray formulation for use in female contraception or in the treatment of benign gynecological disorders is described. The nasal preparation is comprised of a GnRH compound and an estrogenic compound in the form of a water-soluble complex with a water-soluble cyclodextrin. The preparation effectively suppresses ovarian estrogen and progesterone production, and prevents signs and symptoms of estrogen deficiency, without a significant increase in the risk of endometrial hyperplasia.

The invention provides a preparation by which an edaravone drug can be targeted to a brain by virtue of a nasal delivery route, and a preparation method of the preparation. The edaravone nasal delivery preparation of the invention consists of an active ingredient, namely edaravone, and pharmaceutically acceptable effective adjuvant materials. The edaravone nasal preparation disclosed by the invention, after administration, can be rapidly absorbed and can rapidly reach the brain and enrich in the brain, so that a drug concentration in the brain, higher than that of an injection, which is administrated by an equivalent dosage, is provided, and a therapeutic effect on corresponding diseases is improved; meanwhile, by reducing edaravone concentrations in blood and other tissues, edaravone adverse reactions such as liver function damage and the like can be relieved; in addition, the compliance of patients can be improved; and the preparation is suitable for self-administration, so that the preparation, in the case of diseases, can be timely administrated as soon as possible.

To provide an amorphous composition for nasal administration or for administration by adhering to oral mucosa in which absorption property and chemical and physical stabilities of (2R)—N-(1-benzylpiperidin-4-yl)-3-cyclohexylmethylthio-2-[(4R)-3-tert-butoxycarbonylthiazolidin-4-ylcarbonylamino]propanamide which is useful as an N type calcium channel inhibitor are improved. A preparation comprising the amorphous composition of the present invention has been found to be excellent in physical stability and chemical stability and to be useful as a nasal preparation or a preparation for adhering to the oral mucosa. As a result, the resulting preparation has a high BA value and is useful for prevention and / or the treatment of a disease mediated by the N type calcium channel including pain (such as neuropathic pain, cancerous pain, intractable pain, postoperative pain, acute pain, chronic pain, neuralgia and infectious pain).

The invention relates to the technical field of nasal preparation, and relates to a nasal preparation for treating rhinitis and its preparation method and application. The nasal preparation for treating rhinitis is prepared from, by weight, artemisia rupestris, fried cocklebur fruit, radix angelicae, ephedra, scutellaria baicalensis extract, extractum glycyrrhizae, dementholized peppermint oil, tween-80, and ingredients. The nasal preparation for treating rhinitis is prepared by combining ethnic medicine theory with traditional Chinese medicine theory; compared with the prior art, the dosage of the nasal preparation for treating rhinitis is only 20-30% of that in the prior art; moreover, the nasal preparation for treating rhinitis has significant effects in anti-inflammatory and antiallergic by comparing with the prior art; meanwhile, the nasal preparation is simple in preparation technique, accurate in treatment effect, free from toxic and side effects; the drug is directly effected on the surface of the nasal mucosa; thus the nasal preparation is high in bioavailability, quick and convenient to take effect and good in patient compliance; different dosage forms can be prepared upon patient's demand, thus the nasal preparation can be better applied to treat acute, chronic and allergic rhinitis.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to preparation of a cannabidiol nasal preparation composition for treating post-traumatic stress disorder, and temperature sensitive gel, ion sensitive gel, cubic liquid crystals, and the like are included; the cannabidiol nasal preparation composition has high adhesion in a nasal cavity, residence time isprolonged in the nasal cavity, bioavailability is improved beneficially to exert the pharmacological effect, and brain targeting is achieved; at the same time, the preparation process is simple, stability is high, and compliance of the patient is good; and pharmacodynamic tests prove that the cannabidiol nasal preparation for treating the post-traumatic stress disorder has good anti-depressant andanti-anxiety effects, and can be used for treating the post-traumatic stress disorder.

The invention discloses a medicament for treating cardiovascular and cerebrovascular diseases, which is prepared from original-shaped medicament of Breviscapine or its pharmaceutically acceptable salts as the active constituents. The medicament can be made into nasal preparation, wherein each 1g of the medicament contain 1-200mg of the active constituents

The present invention is one kind of nasal liquid medicine for treating headache and its preparation process. The medicine consists of volatile dahurian angelica oil and volatile Chuanxiong oil as the effective medicine components and pharmaceutically acceptable supplementary material. The medicine is prepared into emulsion form or gel form, such as nasal drop, nasal spray, aerosol, nasal inhalant, etc. The volatile oil as the effective component is preferably extracted through supercritical CO2 circular extraction and separation. The medicine for treating headache has high bioavailability and excellent effect.

The invention provides a gastrodin nasal starch microsphere with bioadhesive properties. The microsphere is prepared by the following method: using starch sodium hydroxide aqueous solution as the water phase; dispersing gastrodin in ethyl acetate to obtain Oil phase; slowly add the oil phase to the water phase at room temperature, and stir in the same direction to obtain O / W colostrum; heat the liquid paraffin containing Span80 to 40-50°C, add the above colostrum into it, and stir in the same direction to emulsify After 20-40 minutes, add the cross-linking agent epichlorohydrin, cross-link at 30-50°C for 3-5 hours, centrifuge, pour off the upper oil phase, and wash the lower layer of microspheres with ethyl acetate, absolute ethanol, and acetone respectively Finally, dry under reduced pressure to obtain the described gastrodin nasal starch microspheres; the gastrodin nasal starch microspheres prepared by the present invention have a long retention time in the nasal cavity, and the drug release speed is stable and complete, which can improve the drug distribution in the brain, biological Utilization and efficacy, and safe and non-toxic.

The invention belongs to the field of pharmaceutical preparations, and discloses a chitosan lipoprotein intranasal administration nanocomposite, comprising lipoprotein nanoparticles, chitosan or / and chitosan derivatives having the effect of promoting absorption of nasal mucosa. The invention also discloses a preparation method of chitosan lipoprotein intranasal administration nanocomposite, comprising: self-assembling chitosan or / and chitosan derivatives and lipoprotein nanoparticles through dynamic force to form a good membrane permeability nasal preparations. The preparation condition of the chitosan lipoprotein intranasal administration nanocomposite is mild, the process is simple, and the industrialized production is easy. The system is safe, non-toxic, and has good biodegradability, which can improve the absorption of lipoprotein drugs in the nasal mucosa and ensure high-efficiency brain targeting. The dosage form is administered by nasal drops, sprays, etc., and is easy to operate, convenient for patients who take the medicine for a long time, and has a good clinical application prospect in the treatment of central nervous system diseases.

The invention relates to the technical field of nasal preparations, and relates to a nasal preparation for treating rhinitis and its preparation method and application; the raw materials contain Xinjiang Artemisia chinensis, fried cocklebur, angelica dahurica, ephedra, scutellaria baicalensis extracts, Licorice extract, peppermint oil, Tween-80, excipients. The nasal preparation for treating rhinitis of the present invention is composed according to the theory of national medicine and traditional Chinese medicine. Compared with the prior art, the dosage of the nasal preparation for treating rhinitis of the present invention is only 20% of the dosage of the prior art. % to 30%, and the nasal preparation for the treatment of rhinitis of the present invention is more effective in anti-inflammation and anti-allergy than the prior art; meanwhile, the preparation process of the present invention is simple and convenient, has definite curative effect, no toxic and side effects, and the medicine directly acts on the nasal mucosa On the surface, it has high bioavailability, quick onset, convenience and good patient compliance. Different dosage forms can be prepared according to the needs of patients, which can be better used to treat acute, chronic and allergic rhinitis.

The invention discloses a self-carrying carrier-free nasal cavity nano-preparation brain-targeted delivery system modified by chitosan oligosaccharides and a preparation method thereof. Including hydrophobic small molecule drugs with neuroprotective effects, polyethylene glycol derivatives, and chitosan oligosaccharides. The present invention also provides a preparation method for the brain-targeted delivery system of the nasal cavity nano-preparation. The first step is to prepare the freeze-dried powder of nanoparticles, and the second step is to stir the freeze-dried powder and chitosan oligosaccharide in isotonic saline before use to form a nasal cavity preparation with good membrane permeability. The preparation method of the system of the present invention is simple, can improve the hydrophobicity of small molecule drugs, reduce toxicity, and enhance neuroprotective effect; there is no carrier, no biodegradation problem and accumulation toxicity, the drug loading rate is as high as 25%, and the membrane is permeable after being modified by chitosan oligosaccharides Absorption is good, and the drug is delivered into the brain with high targeting. The administration method of the dosage form is nasal drop, spray, etc., and the operation is simple, which is convenient for patients who take medicine for a long time, and has a good application prospect in the treatment of nervous system diseases.

The invention discloses a medicament for treating cardiovascular and cerebrovascular diseases, which is prepared from original-shaped medicament of Breviscapine or its pharmaceutically acceptable salts as the active constituents. The medicament can be made into nasal preparation, wherein each 1g of the medicament contain 1-200mg of the active constituents

The invention discloses a composition for constituting the in-situ gel spray for huperzine turbinitis, as well as its preparation method and application. The preparation is a nasal preparation which is in a liquid state in vitro and becomes a gel state when sprayed into a nasal cavity. It uses huperzine A as the active ingredient, supplemented with in-situ gel forming agent, isotonic regulator, pH regulator, preservative, water, etc. It is a nasal in-situ gel spray, which is suitable for the prevention and treatment of elderly people Dementia and middle-aged and elderly memory impairment or improve the memory and learning ability of adolescents. The nasal preparation is in a liquid state in vitro, the dosage is easy to accurately control, and it is convenient to use. When sprayed into the nasal cavity, it can be evenly dispersed on the surface of the nasal mucosa, and diffuses with the nasal mucus to form a gel, which stays in the nasal cavity for a long time and is not easy to be lost. The bioavailability of cerebrospinal fluid, brain, and hippocampus is 2.2 to 2.7 times that of oral administration, and the drug effect is 2 to 4 times that of oral administration. It has small local irritation, low toxicity, and good biocompatibility.